Macaluso, Matthew http://orcid.org/0000-0001-6856-6236
Kinzie, Mark
Cowley, Deborah
Houston, Lillian J.
DeJong, Sandra
Janssen, Furhut
Bentman, Adrienne
Edgar, Laura
Campbell, Brittany
Bowen, Lynneice
Aronowitz, Jeffery
Aoun, Elie
Santiago, Patcho
Keepers, George
Article History
Received: 22 April 2020
Accepted: 17 June 2020
First Online: 8 July 2020
Compliance with Ethical Standards
:
: Jeffrey Aronowitz, D.O., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Adrienne Bentman, M.D., is serving a term as Vice-Chair of the ACGME Psychiatry Review Committee from 2020 to 2022. Lynneice Bowen, M.D., reports non-financial support from the ACGME during her participation on the Milestones 2.0 Working Group. Deborah Cowley, M.D., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Sandra DeJong, M.D., was funded by the ACGME to travel to Milestones 2.0 Working Group Meetings. Lillian Houston, M.D., reports non-financial support from the ACGME during her participation on the Milestones 2.0 Working Group. George Keepers, M.D., served on the American Board of Psychiatry and Neurology Board of Directors from 2011 to 2018, the ACGME Psychiatry Residency Review Committee, the ACGME Psychiatry Milestones Task Force 1.0, and the ACGME Psychiatry Milestones Task Force 2.0. Matthew Macaluso, D.O., has conducted clinical trials research as principal investigator for the following pharmaceutical companies over the last twelve months: (1) Acadia, (2) Allergan, (3) Alkermes, (4) AssureRx/Myriad, (5) Eisai, (6) Lundbeck, (7) Janssen, (8) Neurim, (9) SAGE pharmaceuticals, (10) Suven. All clinical trial and study contracts were with and payments made to the Kansas University Medical Center Research Institute, a research institute affiliated with Kansas University School of Medicine Wichita (KUSM-W). Dr. Macaluso is also a member of the speaker bureau for Janssen pharmaceuticals (esketamine). Dr. Macaluso does not believe these relationships pose a conflict relative to this work.
Free to read: This content has been made available to all.